Fundz

Watching Silexion Therapeutics Corp? See every signal — funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

Silexion Therapeutics Corp

silexion.com
Filed: Jul 29, 2026Modiin, Judea and SamariaCIK: 0002022416Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Silexion Therapeutics announced the initiation of a Phase 2/3 clinical trial for SIL204 targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on July 29, 2026. This milestone advances the company's oncology portfolio in an area of high unmet medical need and may strengthen investor confidence.

Key Takeaways

Phase 2/3 clinical trial for SIL204 has been successfully initiated for locally advanced pancreatic cancer treatment

Trial is being conducted at Tel Aviv Sourasky Medical Center, indicating international clinical development infrastructure

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 29, 2026
Item7.01
CategoryReg FD Disclosure
CIK0002022416
Accession #001-42253
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings